Premium
Cohort study of COX‐1 and COX‐2 expression in canine rectal and bladder tumours
Author(s) -
Knottenbelt C.,
Mellor D.,
Nixon C.,
Thompson H.,
Argyle D. J.
Publication year - 2006
Publication title -
journal of small animal practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.7
H-Index - 67
eISSN - 1748-5827
pISSN - 0022-4510
DOI - 10.1111/j.1748-5827.2006.00094.x
Subject(s) - medicine , proportional hazards model , staining , cyclooxygenase , pathology , transitional cell carcinoma , gastroenterology , cancer , bladder cancer , biology , enzyme , biochemistry
O bjectives :To determine the role that cyclooxygenase‐1 (COX‐1) and cyclooxygenase‐2 (COX‐2) play in malignant transformation in canine transitional cell carcinoma and rectal tumours.M ethods :Histological sections of 21 canine rectal adenocarcinomas and 18 canine transitional cell carcinomas were stained for COX‐1 and COX‐2. Mann‐Whitney non‐parametric tests were applied to determine if there was any relationship between the percentage of cells expressing COX‐1 or COX‐2, and between COX‐1 and COX‐2 staining intensity and age, breed or sex.R esults :For rectal adenocarcinomas, 19·0 per cent of the sections were negative for COX‐1 and COX‐2. A further 38·1 per cent of the sections were negative for COX‐2 but positive for COX‐1, and 38·1 per cent of the sections had rare or occasional single cells positive for COX‐2. No significant differences were found in COX staining when compared with age, breed or sex. For transitional cell carcinomas, all of the sections were positive for COX‐1 and COX‐2. For COX‐2 staining, 16·7 per cent had more than 30 per cent positive cells. For COX‐1 staining, 38·9 per cent had more than 30 per cent positive cells. There was a significant increase in the percentage of COX‐1 positive cells in small breed dogs (P = 0·0337).C linical S ignificance :The variations in COX expression reported in this study may explain the differences in the clinical response of transitional cell carcinomas and rectal adenocarcinomas following treatment with non‐steroidal anti‐inflammatory drugs.